Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy

By sjmartinez • July 11, 2022

Lechner MG, Cheng MI, Patel AY, Hoang AT, Yakobian N, Astourian M, Pioso MS, Rodriguez ED, McCarthy EC, Hugo W, Angell TE, Drakaki A, Ribas A, Su MA. Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. J Immunol. 2022 Jul 11:ji2200244. doi: 10.4049/jimmunol.2200244. Epub ahead of print. PMID: 35817515.

Tags: Endocrinology, Hematology/Oncology, Publications

Medullary Thyroid Carcinoma and Clinical Outcomes in Heterozygous Carriers of the RETK666N Germline Pathogenic Variant

Yip AT, Kim TH, Peluso EM, Jacobsen SE, Yeh MW, Lechner MG. Medullary Thyroid Carcinoma and Clinical Outcomes in Heterozygous Carriers of the RET K666N Germline Pathogenic[...]

Early life stress and pubertal predictors of subsequent substance use in a national diverse sample of adolescents: Sex and substance type matter

Donovan A, Assari S, Grella C, Shaheen M, Richter L, Friedman TC. Early life stress and pubertal predictors of subsequent substance use in a national[...]

Association Between Self-Monitored Blood Glucose and Continuous Glucose Monitoring in Youth With Type 1 Diabetes and Medicaid Insurance

Chan J, Jackson N, Gonzalez Rebollar A, Santana C, Perez de la Garza G, Moin T, Yee JK, Everett E. Association Between Self-Monitored Blood Glucose[...]